The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The importance of risk-stratifying treatment for multiple and smoldering myeloma
Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN, highlights the importance of risk-stratifying treatment for multiple and smoldering myeloma. He explains that current practice involves treating high-risk myeloma differently from standard-risk cases. Dr Rajkumar also notes that it is recommended not to treat patients with low-risk smoldering myeloma. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
